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BRIEF REPORT
Introduction: Cytotoxic chemotherapy remains the mainstay of 
treatment for most patients with advanced disease. Recently, ana-
plastic lymphoma kinase (ALK) expression as a major target for suc-
cessful treatment with ALK inhibitors was detected in a subset of 
non–small-cell lung carcinomas, usually as a result of echinoderm 
microtubule-associated protein-like 4 (EML4)-ALK rearrange-
ments. Although the chromosomal breakpoint within the EML4 gene 
varied, the breakpoint within ALK was most frequently reported 
within intron 19 or rarely in exon 20. Therefore, the different EML4-
ALK variants so far contain the same 3ʹ portion of ALK starting with 
exon 20.
Methods: Here, we report a novel EML4-ALK variant detected by 
reverse transcription polymerase chain reaction  analysis. 
Results: Subsequent sequencing revealed an EML4-ALK fusion 
variant in which exon 6 of EML4 was fused to exon 19 of ALK. It 
occurred in a predominant solid pulmonary adenocarcinoma of a 
65-year-old woman with a clear split signal of ALK in fluorescence in 
situ hybridization analysis and a weakly homogeneous ALK expres-
sion in immunohistochemical staining.
Conclusions: Because of the growing number of fusion variants 
a primary reverse transcription polymerase chain reaction-based 
screening for ALK-positive non–small-cell lung carcinoma patients 
may not be sufficient for predictive diagnostics but transcript-based 
approaches and sequencing of ALK fusion variants might finally 
contribute to an optimized selection of patients.
(J Thorac Oncol. 2012;7: 1198–1199)
Both histomorphological1 and molecular pathological characteristics2 have significant impact on prognosis 
and thus on treatment decisions of non–small-cell lung can-
cer (NSCLC) patients. Cytotoxic chemotherapy remains the 
mainstay of treatment for most patients with advanced dis-
ease, but recently developed tyrosine kinase-based therapeu-
tics are promising specific treatment options.3,4 Anaplastic 
lymphoma kinase (ALK) expression was detected in a sub-
set of NSCLC,5 predominantly adenocarcinomas  of young 
never/light smokers with epidermal growth factor receptor 
and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
(K-RAS) wild type,6 but was also infrequently found in squa-
mous-cell carcinomas5 and adenosquamous carcinomas.7 ALK 
expression is associated with an in-frame gene rearrangement 
that places the kinase domain of ALK under the promoter 
control of echinoderm microtubule-associated protein-like 4 
(EML4).5 Clinical trials demonstrated significant tumor mass 
reduction or stable disease in most patients with NSCLC har-
boring ALK rearrangements and treated with ALK inhibitors.8 
The ALK status of these patients was determined by fluores-
cence in situ hybridization (FISH), which is currently con-
sidered the most sensitive diagnostic tool to identify patients 
who will potentially benefit from ALK inhibitors.6,8 However, 
because of the short size of the inverted ALK gene locus (~12 
megabases), which represents approximately only 5% of the 
total length of chromosome 2, interpretation of FISH analyses 
faces the problem that chromosomal rearrangements occur in 
three dimensions but are visualized in only two dimensions 
on a tissue slide. Thus, using FISH alone for patient selec-
tion results in false negative results9; it is for this reason that 
combined diagnostic approaches with immunohistochemistry 
and reverse transcription polymerase chain reaction (RT-PCR) 
were suggested.9,10
The chromosomal breakpoint within the EML4 gene 
occurs at different sites. The breakpoint within ALK was 
most frequently found within intron 19 or rarely in exon 20 
so that the different EML4-ALK variants described so far 
contain the same coding portion of ALK starting at exon 
20.11–13 However, for RT-PCR–based diagnostic approaches 
it is of utmost importance to recognize all fusion variants of 
EML4-ALK.
CASE PRESENTATION
During routine screening for ALK-positive NSCLC with 
a FISH break-apart probe kit (Vysis; Abbott Laboratories, 
Abbott Park, IL) and immunohistochemistry (IHC) against 
ALK (clone ALK01; DISCOVERY Staining Module; Ventana, 
Tucson, AZ), we identified the predominant solid pulmonary 
adenocarcinoma of a 65-year-old woman with a clear split 
signal and a weak, but homogeneous, ALK expression (Fig. 1). 
In RT-PCR analysis for EML4-ALK variants (V1–V3) we 
identified an unusual large product (233 bp) using a forward 
primer located in exon 6 of EML4 and a reverse primer within 
exon 20 of ALK. The amplicon exceeded the expected size of 
about 105 bp. Subsequent Sanger sequencing of this RT-PCR Copyright © 2012 by the International Association for the Study of Lung Cancer
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product revealed a novel EML4-ALK fusion transcript in 
which exon 6 of EML4 was fused to exon 19 of ALK (Fig. 1).
DISCUSSION
This is the first report of an EML4-ALK fusion variant 
with a fusion of EML4 exon 6 to ALK exon 19. To date, the 
reported fusion variants all include exon 20 as the first exon of 
the 3′ ALK portion in EML4-ALK fusion variants. Therefore, 
the possible presence of exon 19 of ALK should be considered 
for RT-PCR-based screening approaches. The expression of 
ALK at the protein level indicates functional and thus poten-
tial therapeutic relevance.
Other yet known non-EML4 fusion partners of ALK 
include TRK-fused gene (TFG)14, kinesin family member 5 
(KIF5),13 and kinesin light chain 1 (KLC1)15 and are also asso-
ciated with ALK expression. Although the response to ALK 
inhibitors in these cases is unknown yet, the large and herein 
expanded heterogeneity of ALK fusions in relation to the over-
all low frequency questions the suitability of solely RT-PCR–
based screening approaches. Thus, RT-PCR-based approaches 
for specific variant detection should only be used to ultimately 
clarify critical cases from FISH and IHC analyses. Because 
FISH and IHC alone can lead to false negative results, the 
combined use of both methods is currently the most reliable 
approach to screen for ALK-positive NSCLC. However, from 
other tyrosine kinases currently used for targeted therapies, 
e.g., epidermal growth factor receptor, it is well known that 
different mutations also have a different therapy response. 
Therefore, transcript-based approaches and sequencing of 
ALK fusion variants might finally contribute to an optimized 
selection of patients who will benefit from ALK inhibitors.
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FIGURE 1. Immunohistochemistry 
of ALK (A) and ALK break-apart fluo-
rescence in situ hybridization (B) of a 
predominant solid adenocarcinoma 
of the lung with an EML4 exon 6—
ALK exon 19 fusion variant (C). ALK, 
anaplastic lymphoma kinase; EML4, 
echinoderm microtubule-associated 
protein-like 4.
